 |
|
Estrogen and Progesterone Receptors in Melanocytic LesionsOccurrence in Patients With Dysplastic Nevus Syndrome
Darrel L. Ellis, MD;
Ronald G. Wheeland, MD;
Herman Solomon, MD
Arch Dermatol. 1985;121(10):1282-1285.
Abstract
• Estrogen and progesterone binding studies in a series of 22 melanocytic lesions from 14 patients with the dysplastic nevus syndrome were done using a fluorescent estrogen and progesterone binding technique. Melanocytic lesions from these patients, including primary cutaneous melanomas, dysplastic nevi, and benign nevi, contained large numbers of estrogen and progesterone binding cells. Comparison is made to a series of control intradermal nevi that had little or no detectable estrogen or progesterone binding. Increased hormonal binding, and possibly responsiveness, is seen in melanomas, melanoma precursor lesions such as dysplastic nevi and congenital nevi, as well as benign nevi from patients with the dysplastic nevus syndrome.
(Arch Dermatol 1985;121:1282-1285)
Author Affiliations
From the Department of Dermatology, University of Oklahoma Health Sciences Center, Oklahoma City (Drs Ellis and Wheeland), and the Department of Medicine, University of Kansas, Wichita (Dr Solomon). Dr Ellis is now with Vanderbilt University, Nashville, Tenn, and Dr Wheeland is now with the Cleveland Clinic Foundation.
Footnotes
Accepted for publication June 18, 1985.
Reprints not available.
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Fetal Cell Microchimerism and Cancer: A Nexus of Reproduction, Immunology, and Tumor Biology
Kallenbach et al.
Cancer Res. 2011;71:8-12.
ABSTRACT
| FULL TEXT
Absence of Estrogen Receptor in Human Melanoma as Evaluated by a Monoclonal Antiestrogen Receptor Antibody
Flowers et al.
Arch Dermatol 1987;123:764-765.
ABSTRACT
Estrogen Receptors in Malignant Melanoma
Delarue et al.
Arch Dermatol 1987;123:159-160.
ABSTRACT
|
